Clinical Trial Update: Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites [Phase 2]

View source ↗

Summary

Sanofi conducted a Phase 2 dose-ranging trial of satavaptan in hyponatraemic patients with cirrhotic ascites; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Cirrhosis of the Liver

Drugs mentioned

• Satavaptan (satavaptan)

Snippet

Sponsor: Sanofi | Conditions: Ascites, Liver Cirrhosis | Phase 2 | Status: COMPLETED